Wojcik Ewa, Tarapacz Jadwiga, Rychlik Urszula, Stasik Zofia, Sas-Korczynska Beata, Skotnicki Piotr, Kulpa Jan K
Clin Lab. 2016 Sep 1;62(9):1625-1632. doi: 10.7754/Clin.Lab.2016.151212.
The aim of the present study was to compare the diagnostic utility of HE4 with NSE, ProGRP, CYFRA 21-1, CEA, and CA 125 and evaluate their prognostic value in patients with small-cell lung cancer (SCLC).
HE4, ProGRP, NSE, CYFRA 21-1, CEA, and CA 125 assays were performed in 63 patients with smallcell lung cancer (limited disease (LD) - 41, extensive disease (ED) - 22) and in 66 individuals of the reference group.
Area under the ROC curves for HE4, ProGRP, NSE, CA 125, CYFRA 21-1, and CEA were 0.884, 0.923, 0.826, 0.796, 0.739, and 0.704, respectively. The tumor marker serum concentrations were associated with tumor stage (HE4, ProGRP, NSE, CYFRA 21-1, CEA), and disease progression occurred within one year (HE4, ProGRP, NSE, CYFRA 21-1). The tumor advancement, performance status, gender and tumor markers, except CEA and CA 125, were significantly associated with survival. Independent, unfavourable prognostic factors included extensive disease (HR 4.14, p < 0.0001) and NSE concentration above 35 g/l (HR 2.62, p = 0.0009).
Diagnostic utility of HE4 was similar to that of NSE and ProGRP. Complementary to NSE, determination of HE4 seems to be helpful in evaluation of SCLC patients' prognosis.
本研究旨在比较人附睾蛋白4（HE4）与神经元特异性烯醇化酶（NSE）、胃泌素释放肽前体（ProGRP）、细胞角蛋白19片段（CYFRA 21-1）、癌胚抗原（CEA）和糖类抗原125（CA 125）的诊断效用，并评估它们在小细胞肺癌（SCLC）患者中的预后价值。
对63例小细胞肺癌患者（局限性疾病（LD）-41例，广泛性疾病（ED）-22例）和66例参照组个体进行了HE4、ProGRP、NSE、CYFRA 21-1、CEA和CA 125检测。
HE4、ProGRP、NSE、CA 125、CYFRA 21-1和CEA的ROC曲线下面积分别为0.884、0.923、0.826、0.796、0.739和0.704。肿瘤标志物血清浓度与肿瘤分期相关（HE4、ProGRP、NSE、CYFRA 21-1、CEA），且疾病进展发生在1年内（HE4、ProGRP、NSE、CYFRA 21-1）。除CEA和CA 125外，肿瘤进展、体能状态、性别和肿瘤标志物与生存率显著相关。独立的不良预后因素包括广泛性疾病（风险比（HR）4.14，p<0.0001）和NSE浓度高于35μg/L（HR 2.62，p = 0.0009）。
HE4的诊断效用与NSE和ProGRP相似。与NSE互补，检测HE4似乎有助于评估SCLC患者的预后。
